ArticleNature communications2025
An antimicrobial peptide as a potential therapy for bacterial pneumonia that alleviates antimicrobial resistance.
Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Discovery of isokurarinone as an ATCase-engaging lead with potent activity against methicillin-resistantVirulence · 2026Article
- Synergistic Antibacterial and Antibiofilm Effects of (KW)Journal of peptide science : an official publication of the European Peptide Society · 2026Article
- Next-Generation Antimicrobial Peptides for Biofilm-Associated Infections: Engineering, Biomaterial Delivery and AI-Assisted Discovery.Antibiotics (Basel, Switzerland) · 2026Review
- Integrated Genome Mining, Bacterial Co-Culture Activation, and Peptidomic Analyses Identify Antimicrobial Peptide Candidates from South American Bacteria.Antibiotics (Basel, Switzerland) · 2026Article
- [Advances in the diagnosis and treatment of patients with multidrug-resistant bacterial infections combined with severe liver disease].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2026Review
- Role of antimicrobial peptide-based biomaterials in respiratory tract infections control.BMC microbiology · 2026Review
- Protonated Defect-Engineered Carbon Nitride Enables Bio-Interface-Enhanced Photodynamic Antibacterial Activity with Potential Periodontal Application.Materials (Basel, Switzerland) · 2026Article
- Rationally Engineered D-Amino Acid Peptide DT7-3 Combats Multidrug-ResistantMicroorganisms · 2026Article
- Precise Construction of an Antimicrobial Peptide Targeting Bacterial Cell Membranes Derived From Natural Peptides.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Biochemical-knowledge-driven machine learning pipeline for generating potent antimicrobial peptides.Briefings in bioinformatics · 2026Article
- Mechanisms ofMedicina (Kaunas, Lithuania) · 2026Review
- Advanced applications of cationic photosensitizer DHPC in photodynamic eradication of drug-resistant bacteria.Frontiers in microbiology · 2026Article
- Phthalazine-based quaternary ammonium salts: synthesis, biological evaluation and membrane-targeting mechanism againstFrontiers in microbiology · 2026Article
- Discovery of guanidinium salt incorporating cinnamic acid skeleton as new antibacterial agents against Gram-positive bacteria.Frontiers in microbiology · 2026Article
Corrections and comments
- Erratum issued
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bacterial pneumonia remains a global health threat that is worsened by drug-resistant bacteria, underscoring the need for the development of new antimicrobial agents. Antimicrobial peptides are promising new candidates with broad-spectrum activity and low potential for resistance development. Here, we report a linear antimicrobial peptide (AMP) that consists of four repeating units of (D-tryptophan)-(D-arginine)-(D-lysine). This peptide exhibits high stability and robust antimicrobial activity against multidrug-resistant bacteria, such as methicillin-resistant Staphylococcus aureus and Klebsiella pneumoniae, and improved biocompatibility. Furthermore, the AMP shows low potential for resistance development and the ability to alleviate resistance and restore antibiotic sensitivity due to multiple mechanisms, including membrane targeting and non-membrane lysis (DNA binding, reactive oxygen species accumulation, ATP depletion, metabolic interference). In vivo, the peptide showed promising therapeutic efficacy in a model of methicillin-resistant Staphylococcus aureus and K. pneumoniae pneumonia, as well as in a lipopolysaccharide-induced lung injury model.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.